Clinical Trials
A relentless disease calls for a relentless focus on helping patients and families.
PFIC clinical trials | committed to making a difference
The PEDFIC Program
Albireo is committed to advancing science and drug development with the goal of making a difference in the lives of those families affected by PFIC. As part of this commitment, Albireo is sponsoring the PEDFIC clinical trial program to evaluate a potential treatment for this disease.
To learn more about ongoing studies for patients living with cholestatic liver disease, please visit clinicaltrials.gov, or contact Albireo Medical Information (857.378.2035 or medinfo@albireopharma.com) or complete the form below.
Expanded Access in Progressive Familial Intrahepatic Cholestasis (PFIC)
Albireo hopes to provide access to the investigational compound odevixibat for all eligible patients to the greatest extent possible. The Odevixibat PFIC Expanded Access Program (EAP) will provide access initially to eligible patients who have no other therapeutic options and do not qualify for, or have access to, current clinical trials. Timing of availability will vary due to country-specific and local regulations. Our aim is to make the EAP available to more patients over time.
If you or someone you are caring for is living with PFIC and would like to learn more about the EAP, contact your physician. Learn more.
Stay informed
To receive PFIC updates and information, complete the form below. We’ll keep your entries confidential and only provide you with the requested information.
By clicking “Submit”, I agree that Albireo may use my information to send materials related to PFIC clinical trials and studies, as well as other information about PFIC. I understand that I can opt out at any time and that all personal information I have submitted will be kept confidential in accordance with Albireo’s privacy policy.